Plasma Pharmacokinetics of the Lactone and Carboxylate Forms of 20(S)-Camptothecin in Anesthetized Rats
- 1 January 1993
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 10 (10) , 1451-1457
- https://doi.org/10.1023/a:1018919224450
Abstract
20(S)-Camptothecin exists in equilibrium between its lactone (CPT) and its carboxylate forms (Na-CPT) under simulated physiological conditions, with the equilibrium favoring the carboxylate form. The rates of lactone hydrolysis were studied in plasma, serum albumin, and blood and were found to be faster than in aqueous buffers at equivalent pH values. From mechanistic information and in vivo activity data, the lactone appears to be the active form of the drug. It has been argued, therefore, that if an equilibrium existed between the lactone and the carboxylate, Na-CPT could be used to deliver the lactone effectively. In the present study, plasma pharmacokinetics were performed in sodium pentobarbital-anesthetized rats treated with both CPT (lactone) and the sodium salt of camptothecin (carboxylate, Na-CPT) and the lactone and carboxylate, as well as the total drug, concentration versus time profiles were assessed. It was found that plasma concentrations and AUC values for the lactone were significantly higher after dosing with CPT than after dosing with Na-CPT. After i.v. administration, the ratio of plasma lactone to carboxylate was skewed by the apparent rapid and extensive uptake of the lactone into tissues and the rapid clearance of both species. From our results, it appears that the lower in vivo activity of Na-CPT compared to that from CPT administration might be attributed to the altered conversion of carboxylate into lactone in vivo compared to that predicted from in vitro data.Keywords
This publication has 17 references indexed in Scilit:
- A kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some AnaloguesJournal of Pharmaceutical Sciences, 1992
- High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasmaJournal of Pharmaceutical and Biomedical Analysis, 1990
- Determination of camptothecin in biological fluids using reversed-phase high-performance liquid chromatography with fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1990
- Mean Interconversion Times and Distribution Rate Parameters for Drugs Undergoing Reversible MetabolismPharmaceutical Research, 1989
- DNA TOPOISOMERASE I-MEDIATED DNA CLEAVAGE AND CYTO-TOXICITY OF CAMPTOTHECIN ANALOGS1989
- DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGSAnnual Review of Biochemistry, 1989
- On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complexBiochemistry, 1989
- STRUCTURE-ACTIVITY STUDY OF THE ACTIONS OF CAMPTOTHECIN DERIVATIVES ON MAMMALIAN TOPOISOMERASE-I - EVIDENCE FOR A SPECIFIC RECEPTOR-SITE AND A RELATION TO ANTITUMOR-ACTIVITY1989
- Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activityJournal of Medicinal Chemistry, 1989
- Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.1972